Scientific publisher Elsevier, Netherlands, has announced that contract research organisation (CRO) Syngene, India, has signed a multi-year contract for its researchers to obtain unlimited access to Reaxys, Elsevier’s chemistry resource. Reaxys is projected to help Syngene enhance its R&D competitiveness and productivity in the Indian pharmaceutical, chemical and agrochemical research environments.
It is expected that the insights given by Reaxys into possible synthetic routes and validated physical property data would help Syngene researchers generate better output in less time at the labs. Access to Reaxys’ validated, curated chemical information is seen to be a key factor in helping Syngene maintain its position in the CRO market. Reaxys is designed to provide information that will enable researchers to innovate effectively.
Apart from Reaxys, Elsevier’s online solutions include SciVerse ScienceDirect, SciVerse Scopus, MD Consult, Nursing Consult, the SciVal suite and MEDai's Pinpoint Review.
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
